Immuneering Corporation
IMRX
$5.02
$0.173.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.65% | 12.57% | 7.59% | -1.60% | -3.70% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.95% | -7.79% | -7.33% | 3.83% | 5.96% |
| Operating Income | 0.95% | 7.79% | 7.33% | -3.83% | -5.96% |
| Income Before Tax | 7.81% | 11.87% | 8.21% | -7.63% | -10.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.81% | 11.87% | 8.21% | -7.63% | -10.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.81% | 11.87% | 8.21% | -7.63% | -10.81% |
| EBIT | 0.95% | 7.79% | 7.33% | -3.83% | -5.96% |
| EBITDA | 0.91% | 7.79% | 7.32% | -3.89% | -6.01% |
| EPS Basic | 45.57% | 40.79% | 32.05% | 9.32% | 0.66% |
| Normalized Basic EPS | 45.16% | 40.40% | 32.17% | 9.48% | 0.85% |
| EPS Diluted | 45.57% | 40.79% | 32.05% | 9.32% | 0.66% |
| Normalized Diluted EPS | 45.16% | 40.40% | 32.17% | 9.48% | 0.85% |
| Average Basic Shares Outstanding | 76.44% | 62.53% | 46.58% | 20.40% | 12.63% |
| Average Diluted Shares Outstanding | 76.44% | 62.53% | 46.58% | 20.40% | 12.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |